local coverage determination
Laws passed in 14 states appear to require commercial payors to cover biomarker tests broadly that meet certain evidentiary criteria, but payors may have a different interpretation.
Medicare Contractor's Final Coverage Decision on NGS Cancer Testing Appeases Industry Stakeholders
Premium
The LCD covers tests that are FDA approved or cleared, have published analytical validity evidence, or are certified by a third party to be aligned with NYSDOH's criteria.
Palmetto Finalizes Medicare Coverage for MRD Cancer Testing
To receive coverage, the patient must have a personal history of cancer where the type and staging are within the intended use of the test.
Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD
The draft LCD would cover the Signatera minimal residual disease test for several solid tumor types and indications, including immunotherapy response monitoring.
Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications
In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.